Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.

Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

GlaxoSmithKline’s checkpoint inhibitor Jemperli has gained a second indication in the US, for the treatment of mismatch repair-deficient solid tumors, affirming the company’s drive to develop a new portfolio of cancer therapies.